Imugene Limited (AU:IMU) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Imugene Limited has announced that its allogeneic CAR T-cell therapy, azer-cel, will be showcased at the 2025 ASTCT Tandem Meetings in Hawaii. The presentation will highlight the therapy’s enhanced pharmacokinetic profile without compromising safety for patients with Diffuse Large B-Cell Lymphoma. This marks a significant step for Imugene in the field of immuno-oncology, potentially boosting investor confidence.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Cuts Stephanopoulos Pay Post-Trump Settlement
- Ford (NYSE:F) Quality Turns In Surprising Win
- Intel (NASDAQ:INTC) Narrows Down Altera Buyers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
